Noile-Immune Biotech Inc. (TYO:4893)
Japan · Delayed Price · Currency is JPY 148.00
0.00 (0.00%)
Aug 27, 2026, 3:30 PM JST
Noile-Immune Biotech Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3,544 | 3,918 | 4,670 | 5,555 | 4,520 | 4,140 |
Cash & Short-Term Investments | 3,544 | 3,918 | 4,670 | 5,555 | 4,520 | 4,140 |
Cash Growth | -17.83% | -16.10% | -15.93% | 22.90% | 9.18% | 62.48% |
Other Receivables | 11 | 26 | 62 | 66 | - | 53 |
Receivables | 11 | 26 | 62 | 66 | - | 53 |
Inventory | 2 | 2 | 8 | 20 | 3 | 4 |
Prepaid Expenses | 35 | 21 | 29 | 38 | 27 | 25 |
Other Current Assets | 45 | 16 | 6 | 38 | 34 | 3 |
Total Current Assets | 3,637 | 3,983 | 4,775 | 5,717 | 4,584 | 4,225 |
Long-Term Investments | 27 | 28 | 24 | 61 | 56 | 45 |
Other Long-Term Assets | - | - | 1 | - | 1 | 1 |
Total Assets | 3,664 | 4,011 | 4,800 | 5,778 | 4,641 | 4,271 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1 | - | - | 1 | - | - |
Accrued Expenses | 31 | 31 | 27 | 29 | 45 | 20 |
Current Income Taxes Payable | 49 | 39 | 32 | 48 | 235 | 51 |
Other Current Liabilities | 4 | 4 | 10 | 8 | 55 | 9 |
Total Current Liabilities | 85 | 74 | 69 | 86 | 335 | 80 |
Other Long-Term Liabilities | 6 | 6 | 7 | 6 | 7 | 6 |
Total Liabilities | 91 | 80 | 76 | 92 | 342 | 86 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 4,054 | 4,047 | 4,047 | 4,045 | 2,787 | 2,537 |
Additional Paid-In Capital | 4,032 | 4,025 | 4,025 | 4,023 | 2,765 | 2,515 |
Retained Earnings | -4,519 | -4,147 | -3,353 | -2,389 | -1,259 | -872 |
Comprehensive Income & Other | 6 | 6 | 5 | 7 | 6 | 5 |
Shareholders' Equity | 3,573 | 3,931 | 4,724 | 5,686 | 4,299 | 4,185 |
Total Liabilities & Equity | 3,664 | 4,011 | 4,800 | 5,778 | 4,641 | 4,271 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 3,544 | 3,918 | 4,670 | 5,555 | 4,520 | 4,140 |
Net Cash Growth | -17.83% | -16.10% | -15.93% | 22.90% | 9.18% | 62.48% |
Net Cash Per Share | 81.82 | 90.48 | 107.86 | 133.96 | 115.40 | 108.06 |
Filing Date Shares Outstanding | 43.35 | 43.3 | 43.3 | 43.3 | 39.58 | 38.31 |
Total Common Shares Outstanding | 43.35 | 43.3 | 43.3 | 43.3 | 39.58 | 38.31 |
Working Capital | 3,552 | 3,909 | 4,706 | 5,631 | 4,249 | 4,145 |
Book Value Per Share | 82.42 | 90.78 | 109.09 | 131.33 | 108.60 | 109.23 |
Tangible Book Value | 3,573 | 3,931 | 4,724 | 5,686 | 4,299 | 4,185 |
Tangible Book Value Per Share | 82.42 | 90.78 | 109.09 | 131.33 | 108.60 | 109.23 |